Please login to the form below

Not currently logged in

Shionogi ADHD drug wins US approval

Shionogi Inc. has won US Food and Drug Administration approval of extended-release Kapvay for attention deficit hyperactivity disorder in children

Shionogi Inc., the US unit of Japan's Shionogi & Co., has won US Food and Drug Administration (FDA) approval of extended-release Kapvay (clonidine hydrochloride), a non-stimulant treatment for attention deficit hyperactivity disorder (ADHD) in children and adolescents ages six to 17 years.

The oral drug, which can also be used as monotherapy, is "the first and only FDA-approved ADHD treatment indicated for use as add-on therapy to stimulant medication," according to the company. The twice-daily, extended-release product is intended to stabilise the peaks and troughs in blood levels throughout the day.

The marketing application included data from two phase III studies showing that, at five weeks of treatment with Kapvay, children and adolescents with ADHD experienced statistically significant improvements in the core symptoms of inattention, hyperactivity and impulsivity.

"Maintenance efficacy has not been systemically evaluated and patients who are continued on longer-term treatment require periodic reassessment," the company noted.

4th October 2010


COVID-19 Updates and Daily News

Featured jobs


Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...
Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....